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Abstract
Rationale An increasing body of evidence links the occur-
rence of sleep continuity disturbances with increased inflam-
mation and both sleep disturbances and inflammation are as-
sociated with clinical depression. Typhoid vaccination results
in a mild inflammatory response that significantly increases
levels of the proinflammatory cytokine, interleukin (IL)-6.
Objectives The present exploratory study aimed to enhance
our understanding of the link between inflammation, sleep
and depression by examining the effects of typhoid vaccine
on the sleep polysomnogram.
Methods We studied the effects of a single injection of ty-
phoid polysaccharide vaccine and placebo (saline solution)
on sleep in 16 healthy male and female participants aged
20–38 years, sleeping at home in a randomized, double-blind,
balanced order, crossover design. Subjective measures of
mood, sleep and adverse effects were elicited and plasma
samples analysed for IL-6 levels.
Results IL-6 levels (in picogramme per millilitre) significant-
ly increased 2 h post vaccine compared to placebo (0.90 vs
0.53, p = 0.026, r = 0.55). Relative to placebo, typhoid vac-
cination produced significant impairment in several measures
of sleep continuity. Total sleep time (in minute) (426.1 vs
410.7, p = 0.005, r = 0.62) and sleep efficiency percent
(94.3 vs 91.5, p = 0.007, r = 0.65) were decreased; with
increases in wake after sleep onset (in minute) (25.5 vs 38.8,
p = 0.007,r = 0.65), total wake (in minute) (34.9 vs 50.3,
p = 0.005,r = 0.67), sleep stage transitions (155.9 vs 173.1,
p = 0.026, r = 0.56), number of awakenings (27.2 vs 36.1,
p = 0.007, r = 0.64) and awakening index (3.8 vs 5.3,
p = 0.005, r = 0.67) (means, significance level and effect size).
Conclusions Inflammatory mechanisms may underlie the im-
pairment in sleep efficiency which is a hallmark of major
depression. Because impaired sleep is also a predictor of ma-
jor depression, there may be a role for suitable anti-
inflammatory approaches in strategies designed to prevent
the onset of depression.
ClinicalTrials.gov (http://www.clinicaltrials.gov):
NCT02628054
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Introduction
A recent systematic review and meta-analysis looking at ex-
perimental sleep deprivation studies as well as patient cohorts
using a wide range of experimental designs including subjec-
tive reports, actigraphy and polysomnography (PSG) conclud-
ed that sleep disturbances and overlong sleep duration are
associated with increases in markers of systemic inflammation
(Irwin et al. 2015). This link appears bidirectional with poor
sleep leading to elevated levels of proinflammatory cytokines,
such as interleukin (IL)-6, as well as the observation that peo-
ple with increased inflammatory markers due to a variety of
reasons, such as rheumatoid arthritis, pregnancy, haemodialysis
and increased age, experience higher levels of insomnia than in
the general population (Erten et al. 2005; Friedman et al. 2005;
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Burgos et al. 2006; Okun et al. 2007; Fragiadaki et al. 2012).
Moreover, both insomnia and chronic inflammatory illnesses
are associated with high rates of comorbid depression (Dickens
et al. 2002; Miller et al. 2009; Pillai et al. 2011; Felger and
Lotrich 2013). Indeed symptoms of insomnia both commonly
precede and co-occur with depression (Pillai et al. 2011).
Taken together, it is plausible that elevated levels of proin-
flammatory cytokines may be partially responsible for many
of the symptoms of major depression such as low mood, in-
somnia and fatigue (Raison et al. 2006; Dantzer et al. 2008).
Meta-analyses indicate raised levels of IL-6 in groups of pa-
tients withmajor depression (Dowlati et al. 2010). People with
chronic disorders, such as rheumatoid arthritis exhibit raised
proinflammatory cytokines and also experience higher rates of
comorbid depression than would be expected in the general
population. In addition, up to 50 % of hepatitis C patients
become clinically depressed whilst receiving treatment with
interferon-α, a recombinant form of inflammatory cytokine
(Raison et al. 2005; Taylor et al. 2014). Indeed, the risk factor
is such that many patients are offered prophylactic antidepres-
sant medication before commencing interferon treatment.
Such prophylactic use has good tolerability and been shown
to reduce the incidence of interferon-induced depression
(Udina et al. 2014).
In order to further elucidate the link between inflammation,
sleep and mood we decided to use an acute inflammatory
challenge in healthy participants. Previous research has shown
that salmonella typhi (typhoid) vaccination stimulates a mild
inflammatory response which results in increased levels of IL-
6, usually without causing significant morbidity (Brydon et al.
2008; Harrison et al. 2009a). Rare side effects include anaphy-
laxis and serum sickness, whilst common reactions include
localized swelling, discomfort and fever. The typhoid vacci-
nation inflammation model has resulted in significant short-
term lowering of mood which has been shown to correlate
with increased activity within the anterior cingulate cortex
during emotional face processing (Wright et al. 2005;
Brydon et al. 2009; Harrison et al. 2009a).
Typhoid vaccination therefore appears a suitable means of
investigating the effects of immune activation on sleep, in
particular sleep continuity measures which appear linked to
inflammatory responses, as well as other sleep architecture
changes often observed in clinical depression (Dantzer et al.
2008; Pillai et al. 2011; Motivala et al. 2005).
Studying healthy participants enables investigation of the
effects of inflammatory challenge in individuals who do not
currently have an inflammatory condition, or alterations to
their sleep patterns due to a sleep disorder or as part of a
depressive condition. We therefore assessed the effect of ty-
phoid vaccination on the PSG in healthy subjects using home-
based ambulatory recording, previously shown to be sensitive
in detecting the effects of psychotropic drugs on the PSG
(Sharpley et al. 1994, 2011).
Methods and materials
Participants and study design
We studied 16 healthy participants (9 female, 7 male; mean
age 26.6 years; range 20–38 years; BMI 23; range 18.8–26.4).
Eleven of the participants had not received the typhoid vac-
cine before. Participants were recruited through local and on-
line advertising. Inclusion criteria included: participant willing
and able to give informed consent, not currently taking any
medications (except the contraceptive pill) and a good sleeper
determined by self-report and a sleep disorders screening in-
terview. Exclusion criteria included: any current or previous
DSM-IV Axis 1 psychiatric disorder (determined using the
Standard Clinical Interview for Diagnostic and Statistical
Manual for Mental Health Disorders- Fourth Edition)
(Spitzer et al. 1995), diagnosis of current sleep disorder, any
significant current medical condition likely to interfere with
the conduct of the study or analysis of data, typhoid vaccina-
tion within the last 3 years, any vaccination within the last
6 months, history of allergies to drugs or vaccines or any
component of the typhoid vaccine, congenital or acquired im-
mune deficiency, bleeding disorder, current or recent physical
illness or infection within previous 2 weeks, steroidal or non-
steroidal anti-inflammatory medication within preceding
2 weeks, current substance misuse, child bearing age and not
using reliable form of contraception, pregnant or breast feed-
ing, and finally, has taken part in a psychological or medical
experiment involving taking any kinds of drugs within the last
6 weeks.
All participants signed and dated the Informed Consent
Form before any study specific procedures were performed.
During the screening visit, in order to characterize the sample,
participants completed the Eysenck Personality Questionnaire
(EPQ) (Eysenck and Eysenck 1975), State Trait Anxiety
Inventory (STAI) (Spielberger et al. 1970) and Beck
Depression Inventory (BDI-II) (Beck et al. 1996) (Table 1).
For the two study visits, participants attended the department
between 1445 and 1730 hours. Following a brief interview to
ensure that there had been no changes in health or medication
since the screening visit that could affect eligibility, each par-
ticipant was given a single 0.5-mL injection of either typhoid
polysaccharide vaccine (Typhim Vi®) (Sanofi Pasteur MSD
Limited, Berkshire, UK) or placebo (0.9 % sodium chloride
saline solution) into the non-dominant deltoid muscle in the
arm in a randomized, double blind, balanced order, cross-over
design with a 7 to 14 day washout period between each study
visit. Each 0.5-mL dose of typhoid vaccine contains 25 μg of
the active substance, purified Vi capsular polysaccharide of
Salmonella typhi (Ty2 strain). The other ingredients are phe-
nol, sodium chloride, disodium phosphate dihydrate, sodium
dihydrogen phosphate dihydrate and water. This vaccine is
generally well-tolerated, but some individuals can experience
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temporary soreness, swelling, redness or hardness at the site of
the injection. Less common side effects can include pyrexia,
headache, nausea, diarrhoea, generally feeling unwell, abdom-
inal pain and asthma with severe reactions being rare. All
participants were closely monitored for 2 h post injection
and a researcher was available by phone throughout the study.
Subjective questionnaires
Participants completed a set of subjective measures of
mood state, hourly, for 4 h post injection. The Positive
and Negative Affect Schedule (PANAS) is a psychometric
scale, with ten descriptives for each positive and negative
affect rated on a five-point Likert Scale ranging from
‘very slightly’ to ‘very much’ (Watson et al. 1988).
Participants were asked to rate how they feel right now
and two scores obtained; positive and negative (range 10–
50). The Bond and Lader visual analogue scales (VAS)
consisting of sixteen 100-mm VAS anchored by antonyms
(e.g. alert–drowsy, lethargic-energetic, etc.), were com-
bined as recommended by the authors to form three mood
factors: alertness, calmness and contentedness with higher
scores reflecting higher subjective feelings of stress (Bond
and Lader 1974). An adverse effects profile looked at the
presence and severity of common adverse effects; nausea,
vomiting, dizziness, headache, loss of alertness, drowsiness
Table 1 Effect of typhoid
vaccine and placebo, on selected
sleep parameters (n = 15)





Placebo 426.1 13.0 3.354 0.005 0.62
Typhoid vaccine 410.7 12.2
Sleep efficiency, % b
Placebo 94.3 0.8 3.171 0.007 0.65
Typhoid vaccine 91.5 1.0
Wake after sleep onset
Placebo 25.5 3.5 −3.183 0.007 0.65
Typhoid vaccine 38.8 4.8
Total wake
Placebo 34.9 3.4 −3.365 0.005 0.67
Typhoid vaccine 50.3 5.0
Sleep stage transitions
Placebo 155.9 8.0
Typhoid vaccine 173.1 9.2 −2.5 0.026 0.56
No. of awakenings
Placebo 27.2 1.9 −3.1 0.007 0.64
Typhoid vaccine 36.1 3.5
Awakening index
Placebo 3.8 0.3
Typhoid vaccine 5.3 0.5 −3.337 0.005 0.67
Sleep onset latency
Placebo 9.4 1.2 −0.851 0.4 0.22
Typhoid vaccine 11.6 2.6
NREM sleep measures
N 1 (stage 1)
Placebo 37.8 2.8 −1.409 0.2 0.35
Typhoid vaccine 45.0 5.2
N 2 (stage 2)
Placebo 140.7 8.8 1.167 0.3 0.30
Typhoid vaccine 133.0 8.2
N3 (SWS)
Placebo 140.8 6.8 1.588 0.1 0.30
Typhoid vaccine 128.7 6.9
REM sleep measures
REM latency
Placebo 65.6 4.9 −0.677 0.5 0.18
Typhoid vaccine 69.5 4.7
REM sleep
Placebo 106.8 6.8 0.739 0.4 0.20
Typhoid vaccine 103.6 5.4
a Sleep parameters expressed in minutes unless stated otherwise
b Sleep efficiency % = actual sleep time/time in bed × 100
Abbreviations: NREM non-rapid eye movement, REM rapid eye movement, SWS slow wave sleep
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and increased and decreased appetite. In addition, participants
were asked to report any other symptoms that they noted.
IL-6 immunoassay
Five milliliter blood samples were collected between February
16, 2015 and July 6, 2015 into an EDTA tube 2 h post injec-
tion, centrifuged for 10 min at 1,250×gwithin 30 min. Plasma
was then stored at −30 °C until assay on September 23, 2015.
On study completion, the plasma samples were transferred in
a single batch, in unlinked anonymised form, for Human IL-6
Immunoassay using a Quantikine® HS (high sensitivity)
ELISA kit (R&D Systems, Abingdon, UK). The intra-assay
and inter-assay coefficients of variation are 7.4 and 7.8 %,
respectively, and the limit of detection of the assay is
0.039 pg/mL.
Polysomnograms
The electrodes were fitted during each study visit and the
participants then returned home to sleep as usual. On each
study night, PSGs were recorded using the Embla Titanium
recording system (Natus Neurology Incorporated, Middleton,
WI 53562 USA). Participants retired and rose at their usual
time, and this was kept constant for both study nights and
preceding nights. We have previously demonstrated that the
use of ambulatory home sleep recordings provides a reliable
and valid method for PSG data collection and does not result
in first night effects often seen in sleep laboratories (Sharpley
et al. 1988, 1990). The industry standard montage, American
Academy of Sleep Medicine (AASM), was used which com-
prises six electroencephalogram (EEG) channels (C3-M2, C4-
M1, O1-M2, O2-M1, F3-M2, F4-M1), two electrooculogram
(EOG) channels (E1-M2 and E2-M2), and submentalis elec-
tromyogram (EMG) channels using three electrodes (Iber
et al. 2007). PSGs were staged in 30-s epochs using the
Embla RemLogic sleep diagnostic software (Natus
Neurology Incorporated, Middleton, WI, USA). RemLogic
adheres to the AASM scoring criteria (Iber et al. 2007).
AASM criteria have reclassified sleep stages and slow wave
sleep (SWS) is now known as N3. Additionally, the PSGs
were edited by one of the authors, an experienced sleep phys-
iologist who was blind to treatment status (ALS). Participants
were instructed not to consume alcohol, high-fat-content
meals and to avoid intensive exercise for 24 h prior to each
study visit. Normal caffeine intake was maintained to ensure
caffeine withdrawal was not an issue. The following morning,
participants removed the electrodes themselves and, within
20 min of waking, participants completed the 10-item Leeds
Sleep Evaluation Questionnaire (LSEQ) (Parrott and
Hindmarch, 1980). This is a standardized VAS looking at four
aspects of sleep: Getting to Sleep (GTS), Quality of Sleep
(QOS), Awake following Sleep (AFS) and Behaviour
following Awakening (BFW) following a medication com-
pared to the participants’ usual sleep. In addition, a final
Adverse Effects profile was completed and participants were
also asked to guess, with degree of certainty, whether they had
received typhoid vaccine or placebo.
Study oversight
The first author vouches for the accuracy and completeness of
the data and for the fidelity of the study to the protocol.
Concealment of randomization was maintained throughout
the entire study for all participants and for all researchers in-
volved in data acquisition and analysis and the code broken
only after all data had been analysed. The randomization
schedule was drawn up by a member of the group not other-
wise involved in the study tomaintain allocation concealment.
Statistical analysis
Sixteen participants were recruited for this study. Based on
previous PSG studies, this has a statistical power of 0.8 to
detect a 5 % change in % sleep efficiency (SE) with <0.05
threshold. Statistical analyses were performed in SPSS ver-
sion 22 (www.ibm.com/software/analytics/spss). Differences
between pairs of sleep nights, LSEQ and IL-6 levels were
assessed using Dependent-means (paired-samples) t test (two
tailed) and effect sizes (r) calculated. Individual mood and
side effect questionnaire data were analysed using a repeated
measures ANOVAwith two within subject factors, ‘treatment’
(placebo versus typhoid vaccine) and ‘time’ (time since treat-
ment administration).
Results
The typhoid vaccine was well tolerated and no participant
dropped out of the study. One participant was removed from
the PSG analysis due to unusual and disturbing noise outside
his house preventing him sleeping on one night. His subjec-
tive pre-sleep data have been included in the analyses. Due to
difficulty obtaining the sample, one participant did not pro-
vide a blood sample.
Demographics
The baseline questionnaires (BDI-II, STAI and EPQ) showed
that the participants’ data were in the normal range [Electronic
supplementary material (ESM) Table S1].
PSGs
Typhoid vaccine produced several changes in sleep continuity
parameters using Dependent means (paired samples) t test
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(two tailed) (Table 1). Specifically, total sleep time (TST) (in
minute) (p = 0.005, r = 0.62) and SE% (p = 0.007, r = 0.65)
were significantly decreased; consistent with this, there were
significant increases in wake after sleep onset (WASO) (in
minute) (p = 0.007, r = 0.65) (Fig. 1), total wake (in minute)
(p = 0.005, r = 0.67), sleep stage transitions (p = 0.026,
r = 0.56), number of awakenings (p = 0.007, r = 0.64) and
awakening index (p = 0.005, r = 0.67) following typhoid
vaccine compared to the saline injection. No other sleep pa-
rameters were significantly altered (all p > 0.05).
Inflammatory marker
IL-6 levels (in picogramme per millilitre) were significantly
increased 2 h post typhoid vaccine (0.90 ± 0.16) compared to
the saline injection (0.53 ± 0.04), (mean ± SE), t(14) = −2.48,
P = 0.026, r = 0.55 (Fig. 2). Despite the increase, no signifi-
cant correlations were found between changes in IL-6 levels
2 h post vaccine and any of the significant sleep continuity
measures.
Subjective questionnaires
All subjective-state measures were unaffected by typhoid ad-
ministration: PANAS,
Bond and Lader VAS and LSEQ (all p values >0.1; ESM
Tables S2 and S3). The Adverse effects profile looked at both
presence and severity of symptoms. The effects were mild and
similar for both typhoid vaccine and placebo condition with
the exception of ‘sore shoulder’, with a significant main effect
of treatment (F = 6.5, df (1, 15), p = 0.023) but no treatment by
time interaction (F = 3.6 df (1, 4), p = 0.063). As expected,
ratings of sore shoulder were greater after typhoid vaccination
than placebo injection. (Fig. Fig. S1). The participants’ ran-
domization guess revealed that participants could guess, de-
spite mild adverse effects, the difference between the typhoid
vaccine and placebo with 13/16 guessing correctly on both
nights but with more certainty on the placebo (62.6 %) com-
pared to typhoid vaccine (55.2 %) occasion.
Discussion
Previous studies in our laboratory have shown that single
doses of psychotropic drugs can cause acute changes in sleep
architecture and continuity (Sharpley et al. 1994, 2011)
Typhoid vaccine has been shown in several healthy volunteer
studies to induce short-term lowering of mood and we have
therefore employed this model to explore the link between
inflammation and sleep markers in depression. (Wright et al.
2005; Brydon et al. 2009; Harrison et al. 2009b).
Our findings suggest that several measures of sleep conti-
nuity, including significant decreases in TST and SE% and
significant increases in WASO, total wake, sleep stage transi-
tions, number of awakenings and awakening index, are
disrupted following typhoid vaccine compared to placebo. In
our study, typhoid vaccine elicited a significant increase in
levels of IL-6 2 h post-dose demonstrating a small but signif-
icant acute inflammatory activation, and suggests the start of
the response that is usually driven by IL-6 and is most likely
responsible for the disruptions to sleep continuity. The mag-
nitude of the increase in IL-6 levels observed in our study are
similar to those found in previous research which sampled at
2 h (Brydon et al. 2009), and a 24-h time course shows that
peak IL-6 levels occur 6–7 h post injection, returning to base-
line levels after 24 h (Paine et al. 2013). It should also be noted
that in depression there does not appear to be a significant
correlation between IL-6 levels in blood and those in CSF
(Sasayama et al. 2013).
However, correlations between IL-6 and sleep continuity
measures were not significant. One possible explanation is
that for procedural reasons, blood was taken 2 h post vaccina-
tion, thus the participants IL-6 levels at bedtime are unknown
and it is thus not possible to determine whether correlations
between IL-6 levels and measures of sleep continuity would
have been significant if taken at a later time point. Moreover,
given by itself, IL-6 appears to have the ability to increase
SWS and SE (Benedict et al. 2009). Therefore, it seems likely
that some other inflammatory mediator is responsible for the
sleep disruption caused by typhoid vaccination. Krueger et al.
(2008) have pointed out that the mechanisms by which cyto-
kines modify sleep probably involves action on local neural
networks with IL-1, for example, enhancing inhibition of
Fig. 1 Effect of typhoid vaccine and placebo on wake after sleep onset









Fig. 2 Effect of typhoid vaccine and placebo on plasma IL-6 (in
picogramme per millilitre) levels. n = 15 paired t test P = 0.026
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hypothalamic glutamatergic neurons. Sleep disruption could
be a consequence of altered activity in these local networks
which prevents the emergence of sleep from co-ordinated neu-
ronal assemblies.
It has been documented that sleep disturbance has an ad-
verse influence on the risk of infectious and inflammatory
disease, the incidence of depression and the occurrence and
progression of illnesses such as cancer and cardiovascular
disease (Dew et al. 2003; Vgontzas et al. 2013; Irwin et al.
2015). Our current research, using typhoid vaccine as an ex-
perimental model, increases our knowledge of the reciprocal
links between inflammation and sleep impairment.
Meta-analyses have shown that during an episode of de-
pression, rapid eye movement (REM) sleep and density are
increased and REM latency, SWS, TST and SE% are de-
creased compared to matched controls (Erten et al. 2005). In
our present study, we did not see the characteristic changes in
SWS and REM sleep associated with depression; however,
impaired sleep continuity, which both predicts and varies with
the clinical state of depression, was apparent. This suggests
that although inflammation could play a role in the sleep con-
tinuity changes that occur in depression, it does not account
for the changes in sleep architecture. However, it is possible
that sleep architecture changes might become apparent if a
stronger inflammatory stimulus was used or if the inflamma-
tory state persisted for a longer time. A recent systematic
review and meta-analysis looking at both cohort and experi-
mental sleep deprivation studies concluded that sleep distur-
bance is associated with increases in markers of systemic in-
flammation (Irwin et al. 2015).
Although the majority of participants correctly guessed the
order they had been given the typhoid vaccine and placebo
injection, few adverse effects were reported and only the inci-
dence of a sore shoulder was significantly different between
the two study conditions, with no participants reporting an
awareness of a sore shoulderfollowing saline injection where-
as at 4 h post typhoid vaccination 3/16 reported soreness and
by the following morning this had increased to 5/16 compared
to 0/16 for the placebo session. However, this accounts for a
minority of participants and all reported this symptom as mild
or moderate. Therefore although we cannot exclude this
symptom as a possible factor to explain the impaired sleep
on the typhoid vaccine night, it is unlikely.
A further limitation was that unlike previous studies
(Wright et al. 2005; Brydon et al. 2009; Harrison et al.
2009b), we were unable to detect acute changes in subjective
mood. It is possible that the mood questionnaires employed in
our healthy, young, mainly student population were not sen-
sitive enough to detect changes between conditions. Thus
whilst typhoid vaccination may be a good model of a mild
inflammatory state, it does not reliably induce depression and
therefore may not be a good way to model an inflammatory-
depressive condition. A discrepancy between subjective sleep,
using the LSEQ, and objective sleep, with PSG, was also
apparent. An average increase in wake time of 15 min spread
over the entire night on the typhoid vaccine session may not
be sufficient to elicit a worsening of subjective sleep when
sleep efficiency is already high in these good sleepers.
In conclusion, our findings indicate that an acute, mild
inflammatory stimulus produces impairments in sleep conti-
nuity resulting in decreased sleep efficiency. Decreased sleep
efficiency is a hallmark of depression and it is possible that
inflammatory mechanisms play a role in this disturbance. In
addition, impaired sleep is a precursor of depression and an
independent predictor of suicidality (Wojnar et al. 2009). In
people suffering from insomnia linked to inflammatory pro-
cesses the use of suitable anti-inflammatory strategies could
improve sleep as well as perhaps preventing the onset of de-
pression and decreasing the risk of suicidality.
Acknowledgments The study was overseen by the Oxford University
Clinical Trials and Research Governance team, received written approval
by the Medical Sciences Interdivisional Research Ethics Committee (MS
IDREC) and sponsored by the University of Oxford. This work was
supported by Oxford University Departmental funds. We thank
Roweida Sammour for her support role in this study.
Compliance with Ethical Standard
Conflict of interest In the last 3 years, PJC has been a paid advisor to
Lundbeck. All other authors declare no conflict of interest.
Open Access This article is distributed under the terms of the Creative
Commons At t r ibut ion 4 .0 In te rna t ional License (h t tp : / /
creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
distribution, and reproduction in any medium, provided you give
appropriate credit to the original author(s) and the source, provide a link
to the Creative Commons license, and indicate if changes were made.
References
Beck AT, Steer RA, Brown GK (1996) Manual for the Beck
depression inventory–II. Psychological Corporation, San
Antonio, TX
Benedict C, Scheller J, Rose-John S, Born J, Marshall (2009)
Enhancing influence of intranasal interleukin-6 on slow wave
activity and memory consolidation during sleep. FASEB J
23:3629–3636
Bond A, Lader M (1974) The use of analogue scales in rating subjective
feelings. Br J Med Psychol 47:211–218
Brydon L, Harrison NA, Walker C, Steptoe A, Critchley HD (2008)
Peripheral inflammation is associated with altered substantia nigra
activity and psychomotor slowing in humans. Biol Psychiatry 63:
1022–1029
Brydon L,Walker C, Wawrzyniak A, Whitehead D, Okamura H, Yajima,
et al. (2009) Synergistic effects of psychological and immune
stressors on inflammatory cytokine and sickness responses in
humans. Brain Behav Immun 23:217–224
3434 Psychopharmacology (2016) 233:3429–3435
Burgos I, Richter L, Klein T, Fiebich B, Feige B, Lieb K, et al. (2006)
Increased nocturnal interleukin-6 excretion in patients with primary
insomnia: a pilot study. Brain Behav Immun 20:246–253
Dantzer R, O’Connor JC, Freund GG, Johnson RW, Kelley KW (2008)
From inflammation to sickness and depression: when the immune
system subjugates the brain. Nat Rev Neurosci 9:46–56
DewMA, Hoch CC, Buysse DJ, Monk TH, Begely AE, Houck PR, et al.
(2003) Healthy older adults’ sleep predicts all-cause mortality at 4 to
19 years of follow-up. Psychosom Med 65:63–73
Dickens C, Mcgowan L, Clark-Carter D, Creed F (2002) Depression in
rheumatoid arthritis: a systematic review of the literature with meta-
analysis. Psychosom Med 64:52–60
Dowlati Y, Herrmann N, Swardfager W, Liu H, Sham L, Reim EK,
Lanctôt KL (2010) A meta-analysis of cytokines in major depres-
sion. Biol Psychiatry 67:446–457
Erten Y, Kokturk O, Yuksel A, Elbeg S, Ciftci TU, Pasaoglu H, et al.
(2005) Relationship between sleep complaints and pro inflammato-
ry cytokines in haemodialysis patients. Nephrology 10:330–335
Eysenck HJ and Eysenck SBG (1975): In: Manual of the Eysenck Personality
Questionnaire (adult and junior). London: Hodder & Stoughton
Felger JC, Lotrich FE (2013) Inflammatory cytokines in depression: neu-
robiological mechanisms and therapeutic implications. Neuroscience
246:199–229
Fragiadaki K, Tektonidou MG, Konsta M, Chrousos GP, Sfikakis PP
(2012) Sleep disturbances and interleukin 6 receptor inhibition in
rheumatoid arthritis. J Rheumatol 39:60–62
Friedman EM, Hayney MS, Love GD, Urry HL, Rosenkranz MA,
Davidson RJ, et al. (2005) Social relationships, sleep quality, and
interleukin-6 in aging women. Proc Natl Acad Sci U S A 102:
18757–18762
Harrison NA, Brydon L, Walker C, Gray MA, Steptoe A, Dolan RJ, et al.
(2009b) Neural origins of human sickness in interoceptive responses
to inflammation. Biol Psychiatry 66:415–422
Harrison NA, Brydon L, Walker C, Gray MA, Steptoe A, Critchley HD
(2009a) Inflammation causes mood changes through alterations in
subgenual cingulate activity and mesolimbic connectivity. Biol
Psychiatry 66:407–414
Iber C, Ancoli-Israel S, Chesson A, Quan S, for the American Academy
of Sleep Medicine (2007) The AASM manual for the scoring of
sleep and associated events: rules, terminology and technical spec-
ifications, 1st edn. American Academy of Sleep Medicine,
Westchester, IL
Irwin MR, Olmstead R, Carroll JE (2015) Sleep disturbance, sleep duration,
and inflammation: a systematic review and meta-analysis of cohort
studies and experimental sleep deprivation. Biol Psychiatry 107:1–13
Krueger JM (2008) The role of cytokines in sleep regulation. Curr Pharm
Des. 14:3408–16
Miller AH, Maletic V, Raison CL (2009) Inflammation and its discon-
tents: the role of cytokines in the pathophysiology of major depres-
sion. Biol Psychiatry 65:732–741
Motivala SJ, Sarfatti A, Olmos L, Irwin MR (2005) Inflammatory
markers and sleep disturbance in major depression. Psychosom
Med 67:187–194
Okun ML, Hall M, Coussons-Read ME (2007) Sleep disturbances in-
crease interleukin-6 production during pregnancy: implications for
pregnancy complications. Reprod Sc 14:560–567
Parrott AC, Hindmarch I (1980) The Leeds sleep evaluation question-
naire in psychopharmacological investigations—a review.
Psychopharmacology 71:173–179
Paine NJ, Ring C, Bosch JA, Drayson MT, Veldhuijzen van Zanten JJ
(2013) The time course of the inflammatory response to the salmo-
nella typhi vaccination. Brain Behav Immun 30:73–79
Pillai V, Kalmbach DA, Ciesla JA (2011) A meta-analysis of electroen-
cephalographic sleep in depression: evidence for genetic bio-
markers. Biol Psychiatry 70:912–919
Raison CL, Borisov AS, Broadwell SD, Capuron L, Woolwine BJ,
Jacobson IM, et al. (2005) Depression during pegylated interferon-
alpha plus ribavirin therapy: prevalence and prediction. J Clin
Psychiatry 66:41–48
Raison CL, Capuron L, Miller AH (2006) Cytokines sing the blues: inflam-
mation and the pathogenesis of depression. Trends Immunol 27:24–31
Sasayama D, Hattori K, Wakabayashi C, Teraishi T, Hori H, Ota M, et al.
(2013) Increased cerebrospinal fluid interleukin-6 levels in patients
with schizophrenia and those with major depressive disorder. J
Psychiatr Res 47:401–406
SharpleyAL, Elliott JM, AttenburrowMEJ, Cowen PJ (1994) Slowwave
sleep in humans: role of 5-HT2A and 5-HT2C receptors.
Neuropharmacology 33:467–471
Sharpley AL, Solomon RA, Cowen PJ (1988) Evaluation of first night
effect using ambulatory monitoring and automatic sleep stage anal-
ysis. Sleep 11:273–276
Sharpley AL, Solomon RA, Cowen PJ (1990) Sleep stability with home
sleep recording and automatic sleep stage analysis. Sleep 13:538–534
Sharpley AL, Rawlings NB, Brain S, McTavish SFB, Cowen PJ (2011)
Does agomelatine block 5HT2C receptors in humans?
Psychopharmacology 213:653–655
Spielberger CD, Gorsuch RL, Lushene RE (1970)Manual for the State-Trait
Anxiety Inventory. at http://ubir.buffalo.edu/xmlui/handle/10477/2895
Spitzer RL, Williams JBW, Gibbon M, et al. (1995) Structured clinical
interview for DSM-IV (SCID). NewYork State Psychiatric Institute,
Biometrics Research, New York, NY
Taylor MJ, Godlewska B, Near J, Christmas D, Potokar J, Collier J, et al.
(2014) Effect of interferon-α on cortical glutamate in patients with
hepatitis C: a proton magnetic resonance spectroscopy study.
Psychol Med 44:789–795
Udina M, Hidalgo D, Navinés R, Forns X, Solà R, Farré M, Capuron L,
Vieta E, Martín-Santos R (2014) Prophylactic antidepressant treat-
ment of interferon-induced depression in chronic hepatitis C: a sys-
tematic review and meta-analysis. J Clin Psychiatry 75:1113–1121
Vgontzas AN, Fernandez-Mendoza J, Liao D, Bixler EO (2013)
Insomnia with objective short sleep duration: the most biologically
severe phenotype of the disorder. Sleep Med Rev 17:241–254
Watson D, Clark LA, Tellegen (1988) A development and validation of
brief measures of positive and negative affect: the PANAS scales. J
Pers Soc Psychol 54:1063–1070
Wojnar M, Ilgen MA, Wojnar J, McCammon RJ, Valenstein M, Brower KJ
(2009) Sleep problems and suicidality in the National Comorbidity
Survey Replication. J Psychiatric Research 43:526–531
Wright C, Strike P, Brydon L, Steptoe A (2005) Acute inflammation and
negative mood: mediation by cytokine activation. Brain Behav
Immun 19:345–350
Psychopharmacology (2016) 233:3429–3435 3435
